Revvity, Inc. (NYSE:RVTY) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Revvity, Inc. (NYSE:RVTY) have been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $136.25.

RVTY has been the subject of a number of research reports. KeyCorp increased their price target on shares of Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. Bank of America upgraded Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price objective for the company in a research report on Friday, December 13th. Barclays upped their target price on Revvity from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Raymond James reissued an “outperform” rating and issued a $145.00 price target (up previously from $140.00) on shares of Revvity in a report on Monday, February 3rd. Finally, Sanford C. Bernstein lowered shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 target price on the stock. in a research report on Friday, January 10th.

Revvity Trading Down 1.6 %

Shares of NYSE:RVTY opened at $105.65 on Monday. Revvity has a 1 year low of $97.32 and a 1 year high of $129.50. The firm has a fifty day moving average price of $115.16 and a 200 day moving average price of $117.14. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $12.69 billion, a PE ratio of 47.81, a P/E/G ratio of 3.82 and a beta of 1.06.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, beating the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the prior year, the firm earned $1.25 EPS. Analysts expect that Revvity will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity’s dividend payout ratio (DPR) is 12.67%.

Insider Buying and Selling

In other Revvity news, insider Tajinder S. Vohra sold 5,492 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total transaction of $641,520.52. Following the completion of the transaction, the insider now owns 19,652 shares in the company, valued at approximately $2,295,550.12. This represents a 21.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Joel S. Goldberg sold 15,170 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the sale, the insider now owns 33,400 shares in the company, valued at approximately $4,232,782. This trade represents a 31.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.68% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Revvity

Hedge funds have recently modified their holdings of the stock. Cerity Partners LLC lifted its stake in Revvity by 7.4% in the 3rd quarter. Cerity Partners LLC now owns 17,130 shares of the company’s stock valued at $2,188,000 after purchasing an additional 1,174 shares during the last quarter. FMR LLC lifted its stake in shares of Revvity by 40.8% during the 3rd quarter. FMR LLC now owns 155,556 shares of the company’s stock worth $19,872,000 after buying an additional 45,040 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Revvity by 23.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 37,805 shares of the company’s stock worth $4,830,000 after buying an additional 7,237 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Revvity by 7.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 684,078 shares of the company’s stock worth $87,391,000 after acquiring an additional 48,700 shares during the period. Finally, Public Sector Pension Investment Board lifted its holdings in Revvity by 14.9% during the 3rd quarter. Public Sector Pension Investment Board now owns 5,383 shares of the company’s stock worth $688,000 after purchasing an additional 700 shares during the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.